SCHEMBL14710561

SCHEMBL14710561

CCOC(=O)c1c(-c2ccc(Br)cc2)ncn1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
IDO1 P14902 1/20 0.47
TARBP2 Q15633 1/20 0.47
MEN1 O00255 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 5/20 0.46
TP53 P04637 1/20 0.46
CA12 O43570 1/20 0.45
CA9 Q16790 1/20 0.45
CACNA1F O60840 1/20 0.45
ABCB1 P08183 1/20 0.45
CACNA1D Q01668 1/20 0.45
CACNA1S Q13698 1/20 0.45
CACNA1C Q13936 1/20 0.45
SIRT2 Q8IXJ6 1/20 0.44
DUSP3 P51452 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20028095 0.87 SMN1; SMN2 (0.55) MEN1NPC1RAB9AKMT2AMAPT
SCHEMBL30785985 0.83 IDO1 (0.42) HTTIDO1MEN1NPC1RAB9A
SCHEMBL22230807 0.83 IDO1 (0.42) HTTIDO1MEN1NPC1RAB9A
SCHEMBL14710604 0.81 KDM4C (0.43) MEN1NPC1KMT2AMAPTTP53
SCHEMBL15882297 0.80 HTT (0.41) HTTIDO1TARBP2MEN1NPC1
SCHEMBL14711408 0.80 HTT (0.49) HTTIDO1TARBP2MEN1NPC1
SCHEMBL30785989 0.78 MAPK1 (0.40) HTTIDO1MEN1NPC1RAB9A
SCHEMBL22230842 0.78 MAPK1 (0.40) HTTIDO1MEN1NPC1RAB9A
SCHEMBL5937208 0.76 ALDH1A1 (0.47) HTTRAB9AKMT2AMAPTTP53
SCHEMBL14711251 0.75 TARBP2 (0.53) HTTIDO1TARBP2MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12377083-B2 Lysophosphatidic acid receptor antagonist and preparation method therefor WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2025-08-05 US disclosed
CN-112771027-B Lysophosphatidic acid receptor antagonists and process for preparing the same 武汉朗来科技发展有限公司 2024-03-05 CN disclosed
US-20220079928-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2022-03-17 US disclosed
US-20220079928-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2022-03-17 US disclosed
EP-3912975-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR Wuhan LL Science And Technology Development Co., Ltd. (CN) 2021-11-24 EP disclosed
EP-3912975-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR Wuhan LL Science And Technology Development Co., Ltd. (CN) 2021-11-24 EP disclosed
WO-2020147739-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR 武汉朗来科技发展有限公司 2020-07-23 WO disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-20140329871-A1 SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2014-11-06 US disclosed
WO-2013085824-A1 SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2013-06-13 WO disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12377083-B2 Lysophosphatidic acid receptor antagonist and preparation method therefor LPAR1, LPAR2, LPAR4 HTT 3117/4885IDO1 2866/4885TARBP2 4721/4885
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 HTT 3090/4885IDO1 3343/4885TARBP2 4589/4885
US-20140329871-A1 SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF MMP1, COL1A1, COL2A1 HTT 3815/4885IDO1 744/4885TARBP2 4197/4885
US-20220079928-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR LPAR1, LPAR2, LPAR4 HTT 3117/4885IDO1 2866/4885TARBP2 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.